Vecabrutinib作为非共价BTK/ITK抑制剂治疗慢性淋巴细胞白血病的模型评估
共价BTK抑制剂(如依鲁替尼)治疗慢性淋巴细胞白血病(CLL)有效,但BTK C481S突变导致耐药。本研究对下一代非共价BTK抑制剂vecabrutinib进行临床前表征,发现其保留对C481S BTK突变体的抑制活性,在Eμ-TCL1小鼠模型中减少肿瘤负荷并显著改善生存,且对T细胞活化增殖影响较小,与venetoclax联用增强疗效。
要点
- Vecabrutinib在体外保留对BTK C481S突变体的抑制效果,类似野生型BTK。
- 在Eμ-TCL1小鼠模型中,vecabrutinib减少肿瘤负荷并显著改善生存。
- Vecabrutinib与venetoclax联用增强疗效并有利重编程微环境。
核心结论
- 非共价BTK/ITK抑制剂vecabrutinib可能对C481S BTK突变CLL有效,同时保留依鲁替尼的T细胞免疫调节功能。
研究设计与样本
- 临床前研究:体外表征vecabrutinib对BTK及C481S突变体的抑制活性,并在 murine Eμ-TCL1 adoptive transfer模型中评估体内效果。
主要发现
- Vecabrutinib在体外保留对C481S BTK突变体的抑制效果,类似野生型BTK。
- 在Eμ-TCL1小鼠模型中,vecabrutinib减少肿瘤负荷并显著改善生存。
- Vecabrutinib治疗降低CD8+效应和记忆T细胞群体,而 naive 群体增加;显著降低调节性CD4+ T细胞频率。
- 与依鲁替尼不同,vecabrutinib对分离T细胞的活化和增殖影响极小。
- Vecabrutinib与venetoclax联用增强疗效,显著改善生存,并有利重编程微环境。
临床怎么用
- Vecabrutinib可能为C481S BTK突变CLL患者提供治疗选择,并保留T细胞免疫调节功能。
- 联合venetoclax可能增强疗效,需进一步临床研究验证。
局限性
- 本研究为临床前研究,结果需在临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Covalent Bruton tyrosine kinase (BTK) inhibitors, such as ibrutinib, have proven to be highly beneficial in the treatment of chronic lymphocytic leukemia (CLL). Interestingly, the off-target inhibition of IL-2-inducible T-cell kinase (ITK) by ibrutinib may also play a role in modulating the tumor microenvironment, potentially enhancing the treatment benefit. However, resistance to covalently binding BTK inhibitors can develop as the result of a mutation in cysteine 481 of BTK (C481S), which prevents irreversible binding of the drugs. In the present study we performed preclinical characterization of vecabrutinib, a next-generation noncovalent BTK inhibitor that has ITK-inhibitory properties similar to those of ibrutinib. Unlike ibrutinib and other covalent BTK inhibitors, vecabrutinib showed retention of the inhibitory effect on C481S BTK mutants in vitro, similar to that of wild-type BTK. In the murine Eμ-TCL1 adoptive transfer model, vecabrutinib reduced tumor burden and significantly improved survival. Vecabrutinib treatment led to a decrease in CD8+ effector and memory T-cell populations, whereas the naive populations were increased. Of importance, vecabrutinib treatment significantly reduced the frequency of regulatory CD4+ T cells in vivo. Unlike ibrutinib, vecabrutinib treatment showed minimal adverse impact on the activation and proliferation of isolated T cells. Lastly, combination treatment with vecabrutinib and venetoclax augmented treatment efficacy, significantly improved survival, and led to favorable reprogramming of the microenvironment in the murine Eμ-TCL1 model. Thus, noncovalent BTK/ITK inhibitors, such as vecabrutinib, may be efficacious in C481S BTK mutant CLL while preserving the T-cell immunomodulatory function of ibrutinib.
引用
- Jebaraj BMC, Müller A, Dheenadayalan RP, et al. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood. 2022. PMID: 34662393. doi:10.1182/blood.2021011516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。